Navigation Links
Micell Technologies Announces Reduced Clinical Trial Sample Size for MiStent® Drug-Eluting Coronary Stent Based on Early Clinical Data
Date:6/29/2011

DURHAM, N.C., June 29, 2011 /PRNewswire/ -- Micell Technologies, Inc. today announced that it has completed its review of the scheduled four-month follow-up on the first 10 patients from the DESSOLVE I first-in-human trial of the MiStent Drug-Eluting Coronary Stent System ("MiStent DES"), an ultra-thin drug-eluting stent distinguished by a rapid-absorbing drug/polymer coating formulation. Based on results observed in the DESSOLVE I trial, Micell has reduced the sample size in its DESSOLVE II CE Mark study from 270 to 171 planned subjects.

DESSOLVE I, the first-in-human study of the MiStent DES comprising 30 patients with documented stable or unstable angina pectoris, completed enrollment earlier this year. The primary endpoint is in-stent late lumen loss, as measured by the angiography core laboratory in de novo lesions ranging in diameter from 2.5 to 3.5 mm and amenable to treatment with a maximum 23 mm length stent.

Dennis J. Donohoe, M.D., Micell's Chief Medical Advisor, said, "Encouraging results in minimizing late lumen loss with the MiStent DES in the DESSOLVE I trial has prompted us to reduce the total sample size of our pivotal DESSOLVE II trial, with the full agreement of Micell's clinical advisors and principal investigators following rigorous data evaluation."

The DESSOLVE II CE Mark trial is an ongoing multi-center study of patients with documented stable or unstable angina pectoris. The primary endpoint is superiority of the MiStent DES in minimizing in-stent late lumen loss at nine months, compared to Medtronic's Endeavor® Sprint DES, as measured by the angiography core laboratory in de novo lesions ranging in diameter from 2.5 to 3.5 mm and amenable to treatment with a maximum 30 mm length stent.

"We believe that the MiStent DES could provide patients with benefits greater than those offered by currently available drug-eluting stents," commented Arthur J. Benvenuto, Chairman and Chief Executive Office
'/>"/>

SOURCE Micell Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Micell Technologies Enrolls First Patient in CE Mark DESSOLVE II Study of MiStent™ Drug-Eluting Coronary Stent (DES)
2. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
3. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
4. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
5. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
6. New Clinical Studies Confirm Mauna Kea Technologies Cellvizio(R) GI in Range of Procedures
7. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
8. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
9. Senesco Technologies Initiates Preclinical Studies for Cancer Target
10. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
11. Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 2014 Galmed Pharmaceuticals Ltd. (Nasdaq: ... focused on the development and commercialization of a ... diseases and cholesterol gallstones, announced today that the ... approved its request for Fast Track Designation of ... Non-Alcoholic Steato-Hepatitis, or NASH.  FDA ...
(Date:9/23/2014)... 2014  MEDIMETRIKS PHARMACEUTICALS today announced that ... have been elected to Medimetriks, Board of Directors ... who will serve on Medimetriks, Audit Committee, brings ... the Company.  Mr. Lary is currently Managing Director, ... institutional investment firm.  Mr. Lary is responsible for ...
(Date:9/23/2014)... 23, 2014  Vesselon, Inc. today announced the appointment ... effective September 15, 2014. Dr. Raths, appointment follows Vesselon,s ... agent to market a private preferred Series A round ... treatment. "Jurgen,s deep experience across multiple functional ... asset to Vesselon as we develop our device that ...
Breaking Medicine Technology:Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 2Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 3Medimetriks Pharmaceuticals, Inc. Welcomes Independent Directors Andrew Lary and William Resnick to its Board of Directors 2Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 2Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 3
(Date:9/23/2014)... 2014 SOURCE: Solutions from Our ... were made to Rimidi Diabetes and ... with business solutions to challenges faced by patients and ... collaboration between The Hitachi Foundation, Village ... entrepreneurs with the investment capital, mentoring, and support needed ...
(Date:9/23/2014)... Risperdal lawsuits ( http://www.drugbot.com/risperdal/lawsuit/ ) continue ... Liebhard LLP reports. According to an Order issued in ... 19th, the Court has dismissed fraud and negligence per ... on behalf of a man who allegedly developed gynecomastia ... use of Risperdal. In dismissing the Plaintiff’s negligence per ...
(Date:9/23/2014)... TUESDAY, Sept. 23, 2014 (HealthDay News) -- The ... million in additional funding in scientific trials to ... and clinical studies. The supplemental monies were ... fields, including basic immunology, cardiovascular physiology, neural circuitry, ... Sept. 23. "This funding strategy demonstrates our ...
(Date:9/23/2014)... They are common suggestions to remedy stress: You just ... out and see people. , Turns out all ... a lot better a new large scale study ... depression, less perceived stress and enhanced mental health and well-being, ... with partners from De Montfort University, James Hutton Institute, and ...
(Date:9/23/2014)... that you may want to get screened and treated ... knife. According to a first-of-its-kind study in the ... journal of the American Society of Anesthesiologists (ASA), patients ... condition prior to surgery are less likely to develop ... , "OSA is a common disorder that affects millions ...
Breaking Medicine News(10 mins):Health News:$100,000 Awarded to Rimidi Diabetes and TruClinic for Health Business Solutions that Benefit Patients and Providers 2Health News:$100,000 Awarded to Rimidi Diabetes and TruClinic for Health Business Solutions that Benefit Patients and Providers 3Health News:$100,000 Awarded to Rimidi Diabetes and TruClinic for Health Business Solutions that Benefit Patients and Providers 4Health News:$100,000 Awarded to Rimidi Diabetes and TruClinic for Health Business Solutions that Benefit Patients and Providers 5Health News:Risperdal Lawsuit News: Fraud, Negligence Per Se Claims Dismissed from Florida Complaint, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuit News: Fraud, Negligence Per Se Claims Dismissed from Florida Complaint, Bernstein Liebhard LLP Reports 3Health News:NIH Adds $10M to Encourage Gender Balance in Clinical Trials 2Health News:Beating stress outdoors? Nature group walks may improve mental health 2Health News:New research suggests sleep apnea screening before surgery 2
... their families to take the following steps:, , ... When you are sick, keep your distance from others to protect them from ... you are sick to help prevent others from catching your illness. Cover your ... and nose with a tissue when coughing or sneezing. It may prevent those ...
... The following is a joint statement from Bruce Yarwood, ... and National Center for Assisted Living (AHCA/NCAL), and Alan ... Home Care: We commend Senators Baucus and Grassley for ... health care policy reforms that will impact every American ...
... April 29 Pennsylvania,s chief agriculture and ... improve national and state food safety initiatives at the ... in Harrisburg. Agriculture Secretary Dennis Wolff and Health Secretary ... in protecting the food supply and responding to outbreaks, ...
... Almost half of those in ICU had deficient levels, study ... levels are deficient in many critically ill patients, new research ... almost half of people in an intensive care unit were ... to be common in seriously ill patients," said study author ...
... PALO ALTO, Calif., April 29 Varian Medical Systems ... from continuing operations of $0.64 per diluted share in ... earnings from continuing operations of $0.57 per diluted share ... research instruments operation, net earnings per diluted share in ...
... Sangamo BioSciences, Inc. (Nasdaq: SGMO ) today ... first quarter ended March 31, 2009, Sangamo reported a consolidated ... to a net loss of $8.0 million, or $0.20 per ... 31, 2009, the company had cash and cash equivalents, marketable ...
Cached Medicine News:Health News:Workforce Swine Flu Pandemic Survival Preparedness Tips For Business 2Health News:National Long Term Care Leaders Praise Overall Baucus Health Reform Effort, Express Specific Concerns Moving Forward 2Health News:Pennsylvania Governor's Food Safety Council Meets to Discuss Food Supply Protection 2Health News:Critically Ill Patients Lack Vitamin D 2Health News:Critically Ill Patients Lack Vitamin D 3Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 2Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 3Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 4Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 5Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 6Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 7Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 8Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 9Health News:Sangamo BioSciences Reports First Quarter 2009 Financial Results 2Health News:Sangamo BioSciences Reports First Quarter 2009 Financial Results 3Health News:Sangamo BioSciences Reports First Quarter 2009 Financial Results 4Health News:Sangamo BioSciences Reports First Quarter 2009 Financial Results 5Health News:Sangamo BioSciences Reports First Quarter 2009 Financial Results 6Health News:Sangamo BioSciences Reports First Quarter 2009 Financial Results 7
Bone Curette, 145 mm...
Kevorkian Collector Endocervical Curette is a stainless-steel curette with rounded tip....
Cobb Curettes, 11 inches...
...
Medicine Products: